Document is current

Documents that mention this clinical trial

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499

Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285

Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761

Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303

Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645

Deregulation of HLA-I in cancer and its central importance for immunotherapy
https://doi.org/10.1136/jitc-2021-002899

Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595

1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216

184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184